mProve aims to ‘go beyond’ patient engagement with study services hub

By Melissa Fassbender contact

- Last updated on GMT

(Image: iStock/Pinkypills)
(Image: iStock/Pinkypills)
mProve Health has partnered with Greenphire to provide payment solutions on its patient engagement app – bringing it one step closer to creating a mobile hub for all study services, says CEO.

mProve Health provides mobile technology for patient engagement and electronic clinical outcome assessments (eCOA). Greenphire is a clinical payment automation company.

Through the companies’ partnership, clinical trial participants receiving payments or reimbursements via Greenphire’s ClinCard will gain real-time access to their balance and payment history through mProve’s app, mPal.

Giving patients transparency into payment balance and transactions, along with immediate access to funds via their ClinCard, eliminates any financial hurdles that might deter a participant from fulfilling their study commitments or continuing in the trial,​” Jeff Lee, CEO at mProve Health told Outsourcing-Pharma.com. “It’s only fitting to combine these solutions in a single, mobile app.​”

mProve launched its combined patient engagement and electronic patient reported outcomes (ePRO) app in 2013. As Outsourcing-Pharma.com previously reported​, the company has been growing in response to demand for patient-operated mobile technology in clinical trials.

The vision for our mPal solution is to go beyond standard patient engagement and ePRO, to create a mobile hub that includes all study services (i.e. transportation, lab courier, etc.) in a single solution​,” explained Lee.

Adding patient payment information via the integration with Greenphire’s ClinCard brings us one step closer to offering patients all the services they could need for any trial,​” he said.

Related news

Show more

Related products

VDS groß

Meet the challenges of complex injectables

Vetter Pharma International GmbH | 07-Nov-2017 | Technical / White Paper

In the time it takes from the exciting discovery phase to the rigorous demands of a commercial launch, unexpected scientific and technical challenges can...

lyo_vials

Process Development for Lyophilized Products

Baxter BioPharma Solutions | 30-Oct-2017 | Application Note

Baxter approaches formulation and process development with the intention of identifying the failure points for the product. Knowing where the product fails...

Ocopeptides

Advancing therapeutics for myeloma

Recipharm AB | 04-Sep-2017 | Case Study

Multiple myeloma is the second most common blood cancer in the world and despite survival rates increasing over the last decade, there remains a requirement...

Related suppliers